ABCD1 Knockout Cell Line (HEK293)

The choice depends on whether you are studying ABCD1 (adrenoleukodystrophy protein, ALDP)'s role as the peroxisomal VLCFA transporter or modeling X-linked adrenoleukodystrophy (X-ALD). The Knockout line is the standard tool for asking whether ABCD1 is required for these processes — ABCD1 is a peroxisomal ABC half-transporter that imports very-long-chain fatty acids (VLCFA, C24:0, C26:0) as CoA esters into peroxisomes for β-oxidation; ABCD1 dysfunction causes VLCFA accumulation. Overexpression is useful for studying ABCD1 gain-of-function effects. For peroxisomal disease research, the EDITGENE ABCD1 Knockout in HEK293 is uniquely valuable — ABCD1 loss-of-function mutations cause ⭐⭐ X-linked adrenoleukodystrophy (X-ALD), the most common peroxisomal disorder, with phenotypes ranging from childhood cerebral ALD (the basis of the 'Lorenzo's Oil' story) to adrenomyeloneuropathy (AMN); X-ALD is characterized by VLCFA accumulation, demyelination, and adrenal insufficiency. ABCD2 and ABCD3 paralog expression analysis aids interpretation. Rescue with wild-type or patient-derived ABCD1 mutations enables disease modeling. The knockout is valuable for studying peroxisomal VLCFA metabolism, X-ALD disease mechanisms, and emerging therapeutic approaches (Lorenzo's Oil, Lenmeldy/related gene therapy, Skysona/elivaldogene autotemcel — the FDA-approved 2022 gene therapy for cerebral ALD).

Primary applications: • VLCFA metabolism: very-long-chain fatty acid (C24:0, C26:0) accumulation analysis in ABCD1-null cells — the biochemical hallmark of X-ALD. • X-ALD modeling: rescue with patient-derived ABCD1 mutations for X-linked adrenoleukodystrophy disease modeling. • Peroxisomal β-oxidation: VLCFA peroxisomal β-oxidation flux analysis. • Gene therapy validation: critical genetic null background for testing ABCD1 gene therapy vectors (⭐ Skysona/elivaldogene autotemcel, FDA-approved 2022 for cerebral ALD). EDITGENE recommends this model for researchers investigating peroxisomal VLCFA metabolism, X-ALD disease mechanisms, and ABCD1 gene therapy development.

Yes. ABCD1 rescue experiments require attention to peroxisomal membrane targeting: • Construct design: use a codon-modified ABCD1 sequence with a small tag (FLAG, HA). ABCD1 is a peroxisomal ABC half-transporter (one transmembrane domain + one nucleotide-binding domain) functioning as a homodimer — preserve peroxisomal targeting. • Peroxisomal localization validation: confirm peroxisomal membrane localization before functional assays. • Transport-deficient rescue: Walker A/B motif mutations abolish ATP-dependent VLCFA transport. • X-ALD mutation rescue: patient-derived ABCD1 mutations enable disease modeling. • Functional readout: rescue should restore VLCFA peroxisomal import and β-oxidation, reducing C26:0 accumulation. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.